Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01136876 · ClinicalTrials.gov registry record · Phase 4
Kidney Damage in Patients With Moderate Fall in eGFR
A Phase 4 study, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 4
- Development phase
- 57
- Enrollment target
NCT01136876 is a Phase 4 study that has completed, run by Bracco Diagnostics. The registered enrollment target is 57 participants.
The verdict
NCT01136876, a Phase 4 study, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 57 participants
- Enrollment target
Study Summary
To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR
Interventions
- DRUG Iopamidol
- DRUG Iodixanol-320
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01136876
The ClinicalTrials.gov registry entry for NCT01136876 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Iopamidol is the first listed.
NCT01136876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01136876 about?
NCT01136876 is a clinical study titled "Kidney Damage in Patients With Moderate Fall in eGFR". To compare Iopamidol injection 370 and Iodixanol 320 in evaluating Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with moderate fall in eGFR
What is the current status of trial NCT01136876?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 57 participants. The study started on 2010-11. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01136876?
The interventions under investigation include: Iopamidol (DRUG), Iodixanol-320 (DRUG).
Who is sponsoring clinical trial NCT01136876?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.